- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in RNA therapeutics and obesity, announced today that it has released a white paper describing the health problem posed by the hepatitis B virus (HBV), the substantial unmet need for chronic HBV infected patients, and how Arrowhead's Dynamic Polyconjugate (DPC) enabled RNAi therapeutic in development could potentially address deficiencies of current treatment options.
"Hepatitis B is a global health problem without effective treatment for a vast number of patients with chronic disease. The World Health Organization estimates that 360 million people, or 5% of the world's population, suffer from chronic hepatitis B," said Christopher Anzalone, Ph.D., President and CEO of Arrowhead. "Advances in hepatitis C treatment have drawn considerable attention over the last year, and we see HBV as a similarly high value target. Extensive data from our development programs across multiple in vitro and animal models suggest that we can leverage RNAi and our DPCs to produce a powerful and highly specific candidate to fight HBV."
HBV infection occurs primarily in hepatocytes and long-term infection causes hepatic inflammation that leads to acute and chronic hepatic dysfunction including acute hepatic failure, cirrhosis, and hepatocellular carcinoma. The DPC delivery platform is being employed for the HBV product candidate, which is supported by multiple studies including demonstration in non-human primates of safe and effective delivery of siRNA to hepatocytes and promising data generated through mouse models of HBV using a DPC formulation.
"The development of a DPC-enabled HBV candidate began under Roche and we are very pleased with the progress that our scientists have made," said David Lewis, Ph.D., Vice President of Biology and the site head at Arrowhead's research and development facility in Madison, WI. "We are excited to provide more detail on the DPC platform and the HBV program during upcoming scientific conferences and through future publication in peer-reviewed journals."
The white paper is available on Arrowhead's home page: www.arrowheadresearch.com.
About Arrowhead Research Corporation
Arrowhead Research Corporation is a clinical stage nanomedicine company developing innovative therapies at the interface of biology and nanoengineering. Arrowhead's world-class capabilities and intellectual property covering nucleic acid delivery, siRNA chemistry, and tissue targeting allow it to design and develop therapeutic agents for a wide range of diseases. The company's lead products include CALAA-01, an oncology drug candidate based on the gene silencing RNA interference (RNAi) mechanism, and AdipotideTM, an anti-obesity peptide that targets and kills the blood vessels that feed white adipose tissue. Arrowhead is leveraging its proprietary Dynamic PolyConjugateTM (DPC), Liposomal Nanoparticle (LNP), and RONDELTM delivery platforms to support its own pipeline of preclinical and clinical candidates and to secure external partnerships and collaborations with biotech and pharmaceutical companies.
Safe Harbor Statement under the Private Securities Litigation Reform Act:
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the future success of our scientific studies, our ability to successfully develop drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Arrowhead Research Corporation's most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.
For more information, please click here
Investor Relations Contact:
The Trout Group, LLC
Copyright © Arrowhead Research CorporationIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Arrowhead to Present at Jefferies 2015 Healthcare Conference May 27th, 2015
Interviews/Book Reviews/Essays/Reports/Podcasts/Journals/White papers